Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing Aramchol, a synthetic fatty acid-bile acid conjugate, for liver disease and oncology-related indications. The company is incorporated in Israel and operates through subsidiaries in Israel, Malta, and the United Kingdom, with its securities listed in the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment of Aramchol as a therapeutic candidate for liver disease and oncology indications.
Research and development programs targeting gastrointestinal and GI-related oncology uses.
Intellectual property, licensing, and development capabilities supporting future programs.
Customers
Galmed is primarily a development-stage biopharmaceutical company, so its direct “customers” are not end patients but rather future pharmaceutical partners, licensees, and potential commercial collaborators. Its programs are designed for healthcare providers and patients in liver disease, gastrointestinal disease, and oncology settings once a product reaches commercialization.
Buy or license clinical-stage assets such as Aramchol to expand their therapeutic pipelines.
Would prescribe or administer Galmed’s therapies if approved for liver or GI oncology indications.
Patients with liver disease or GI-related cancers who are the eventual end users of approved drugs.
Partners that support development programs, data generation, or clinical advancement.
Strategy
Galmed’s strategy centers on advancing Aramchol through development for GI and oncology indications and positioning the company as a specialty GI biopharmaceutical platform. The company also appears to be building capability through complementary transactions and partnerships that expand its therapeutic scope and potential commercialization options.
Clinical progress is the main value driver for a development-stage biopharmaceutical company.
A wider indication set can enlarge the addressable market and diversify pipeline risk.
A focused therapeutic platform can improve partnering leverage and strategic differentiation.
Geography
Galmed is incorporated in Israel and maintains subsidiaries in Malta, Israel, and the United Kingdom, while its securities trade in the United States. Its business footprint is therefore international even though the core operating and development structure is centered in Israel and adjacent jurisdictions.
Risks
Galmed faces the classic risks of a development-stage biotech company: clinical failure, regulatory setbacks, and the need to fund long development cycles before commercialization. The company also carries acquisition integration, IP, and going-concern style funding risk, which are especially important because its value depends on advancing a small number of programs successfully.
- Clinical development failureImpact: CriticalLikelihood: Medium
Aramchol is still under evaluation, so negative trial results could materially reduce pipeline value.
Exposure: Lead asset Aramchol
- Capital funding riskImpact: HighLikelihood: High
The company states it will need substantial additional capital to fund operations and development.
Exposure: Operations and R&D funding
- Regulatory approval riskImpact: HighLikelihood: Medium
Drug candidates must clear safety and efficacy hurdles before commercialization.
Exposure: Liver disease and oncology indications
- Intellectual property litigationImpact: MediumLikelihood: Medium
The reports reference infringement, damages, royalties, and legal defense costs.
Exposure: Patent and IP disputes
- Integration risk from acquisitionsImpact: MediumLikelihood: Medium
Acquired assets and businesses must be integrated without disrupting development plans.
Exposure: Colospan-related transaction
Accounting
Judgemental itemsMost development costs are expensed as incurred, which makes earnings highly sensitive to pipeline activity.
Impact: Directly affects operating loss and quarterly comparability
The company discloses that continuation depends on future capital resources and operating plans.
Impact: Important for evaluating balance sheet and financing risk
The Colospan transaction includes revised unaudited pro forma financial statements.
Impact: Can change the presentation of assets, liabilities, and future earnings base
Equity issuance changes the weighted-average share count used in loss per share calculations.
Impact: Affects reported per-share losses
Similar listed companies
Publicly listed companies with a comparable business focus.
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Can-Fite BioPharma Ltd.
CANF · Pharmaceutical Preparations
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
BioLineRx Ltd.
BLRX · Pharmaceutical Preparations
Palisade Bio, Inc
PALI · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026